Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH STROKE D in Acute Ischemic Stroke
NCT07644234Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
- Sponsor
- Sichuan Provincial People's Hospital
- Drugs
- clopidogrelaspirin
- Conditions
- ischemic strokeTransient Ischemic Attack (TIA)
01
Overview
Phase 4, randomised, open-label trial of clopidogrel and aspirin in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Recurrent stroke (including ischemic and hemorrhagic stroke) at 90 days. Planned start Jun 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Shortened Dual Antiplatelet Therapy (7-Day DAPT → Clopidogrel Monotherapy)
7 days of DAPT followed by clopidogrel monotherapy up to day 90.
Standard Dual Antiplatelet Therapy (21-Day DAPT → Single Antiplatelet)
21 days of DAPT followed by single antiplatelet therapy up to day 90.
03
Who it enrols
Adults with acute non-disabling ischemic stroke or high-risk TIA within 48 hours of onset, sensitive to clopidogrel, excluding those with hemorrhagic stroke, atrial fibrillation, or recent use of other antiplatelets/anticoagulants.
04
Endpoints
Primary
Recurrent stroke (including ischemic and hemorrhagic stroke)
Secondary
New stroke
New vascular events
Modified Rankin Scale
New ischemic stroke
Worsening of nerve damage
EuroQol - 5 dimension questionnaire
Beyond the preview
Go deeper on NCT07644234.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644234.